BRENDA - Enzyme Database show
show all sequences of 1.14.14.73

Identification of novel substrates for human cytochrome P450 2J2

Lee, C.; Neul, D.; Clouser-Roche, A.; Dalvie, D.; Wester, M.; Jiang, Y.; Jones III, J.; Freiwald, S.; Zientek, M.; Totah, R.; Drug Metab. Dispos. 38, 347-356 (2010)

Data extracted from this reference:

Application
Application
Commentary
Organism
medicine
enzyme is able to modify antihistamine drugs such as albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol with in vitro intrinsic clearance values ranging from 0.06 to 3.98 microl/min/pmol CYP2J2. Whereas isoform CYP3A4 commonly metabolizes compounds at multiple sites, CYP2J2 metabolism is more restrictive and limited, in general, to a single site for large compounds
Homo sapiens
Crystallization (Commentary)
Crystallization
Organism
homology modeling of structure
Homo sapiens
Organism
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
Homo sapiens
P51589
-
-
Source Tissue
Source Tissue
Commentary
Organism
Textmining
commercial preparation
-
Homo sapiens
-
Substrates and Products (Substrate)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
albendazole + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
albendazole S-oxide + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
amiodarone + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
astemizole + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
cyclosporin + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
danazol + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
mesoridazine + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
additional information
enzyme is able to modify antihistamine drugs such as albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol. The substrates vary in size and overall topology from relatively rigid structures (amiodarone) to larger complex structures (cyclosporine). CYP2J2 metabolism is more restrictive than that of YP3A4 and limited, in general, to a single site for large compounds
744770
Homo sapiens
?
-
-
-
-
thioridazine + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
Application (protein specific)
Application
Commentary
Organism
medicine
enzyme is able to modify antihistamine drugs such as albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol with in vitro intrinsic clearance values ranging from 0.06 to 3.98 microl/min/pmol CYP2J2. Whereas isoform CYP3A4 commonly metabolizes compounds at multiple sites, CYP2J2 metabolism is more restrictive and limited, in general, to a single site for large compounds
Homo sapiens
Crystallization (Commentary) (protein specific)
Crystallization
Organism
homology modeling of structure
Homo sapiens
Source Tissue (protein specific)
Source Tissue
Commentary
Organism
Textmining
commercial preparation
-
Homo sapiens
-
Substrates and Products (Substrate) (protein specific)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
albendazole + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
albendazole S-oxide + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
amiodarone + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
astemizole + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
cyclosporin + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
danazol + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
mesoridazine + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
additional information
enzyme is able to modify antihistamine drugs such as albendazole, amiodarone, astemizole, thioridazine, mesoridazine, and danazol. The substrates vary in size and overall topology from relatively rigid structures (amiodarone) to larger complex structures (cyclosporine). CYP2J2 metabolism is more restrictive than that of YP3A4 and limited, in general, to a single site for large compounds
744770
Homo sapiens
?
-
-
-
-
thioridazine + [reduced NADPH-hemoprotein reductase] + O2
-
744770
Homo sapiens
? + [oxidized NADPH-hemoprotein reductase] + H2O
-
-
-
?
Other publictions for EC 1.14.14.73
No.
1st author
Pub Med
title
organims
journal
volume
pages
year
Activating Compound
Application
Cloned(Commentary)
Crystallization (Commentary)
Engineering
General Stability
Inhibitors
KM Value [mM]
Localization
Metals/Ions
Molecular Weight [Da]
Natural Substrates/ Products (Substrates)
Organic Solvent Stability
Organism
Oxidation Stability
Posttranslational Modification
Purification (Commentary)
Reaction
Renatured (Commentary)
Source Tissue
Specific Activity [micromol/min/mg]
Storage Stability
Substrates and Products (Substrate)
Subunits
Temperature Optimum [°C]
Temperature Range [°C]
Temperature Stability [°C]
Turnover Number [1/s]
pH Optimum
pH Range
pH Stability
Cofactor
Ki Value [mM]
pI Value
IC50 Value
Activating Compound (protein specific)
Application (protein specific)
Cloned(Commentary) (protein specific)
Cofactor (protein specific)
Crystallization (Commentary) (protein specific)
Engineering (protein specific)
General Stability (protein specific)
IC50 Value (protein specific)
Inhibitors (protein specific)
Ki Value [mM] (protein specific)
KM Value [mM] (protein specific)
Localization (protein specific)
Metals/Ions (protein specific)
Molecular Weight [Da] (protein specific)
Natural Substrates/ Products (Substrates) (protein specific)
Organic Solvent Stability (protein specific)
Oxidation Stability (protein specific)
Posttranslational Modification (protein specific)
Purification (Commentary) (protein specific)
Renatured (Commentary) (protein specific)
Source Tissue (protein specific)
Specific Activity [micromol/min/mg] (protein specific)
Storage Stability (protein specific)
Substrates and Products (Substrate) (protein specific)
Subunits (protein specific)
Temperature Optimum [°C] (protein specific)
Temperature Range [°C] (protein specific)
Temperature Stability [°C] (protein specific)
Turnover Number [1/s] (protein specific)
pH Optimum (protein specific)
pH Range (protein specific)
pH Stability (protein specific)
pI Value (protein specific)
Expression
General Information
General Information (protein specific)
Expression (protein specific)
KCat/KM [mM/s]
KCat/KM [mM/s] (protein specific)
744771
Gul
Microbial flavoprotein monoox ...
Rhodococcus jostii, Thermothelomyces thermophilus
Drug Metab. Dispos.
44
1270-1276
2016
-
-
2
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744049
Wu
CYP2J2 and CYP2C19 are the ma ...
Homo sapiens
Antimicrob. Agents Chemother.
57
5448-5456
2013
-
-
-
-
-
-
-
-
1
-
-
2
-
2
-
-
-
-
-
2
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
2
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744770
Lee
Identification of novel subst ...
Homo sapiens
Drug Metab. Dispos.
38
347-356
2010
-
1
-
1
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
1
-
-
8
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
8
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
744610
Rawden
Relative contribution of cyto ...
Homo sapiens
Br. J. Clin. Pharmacol.
49
313-322
2000
-
-
-
-
-
-
2
-
1
-
-
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
744768
Moroni
Chiral sulfoxidation of alben ...
Rattus norvegicus
Drug Metab. Dispos.
23
160-165
1995
-
-
-
-
-
-
1
-
1
-
-
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
745602
Souhaili-El Amri
Albendazole sulfonation by ra ...
Rattus norvegicus
J. Pharmacol. Exp. Ther.
246
758-764
1988
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
-
1
1
1
1
-
-
746557
Souhaili El Amri
Sulphoxidation of albendazole ...
Sus scrofa
Xenobiotica
17
1159-1174
1987
-
-
-
-
-
-
-
-
1
-
-
-
-
1
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
1
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-